Paragon Biosciences LLC

Sage Therapeutics, Inc. has a lot to figure out in the coming weeks, now that the US Food and Drug Administration has approved Zurzuvae (zuranolone) for postpartum depression (PPD) but rejected the d

Emalex Biosciences Inc. significantly expanded on its previous capacity to fund the upcoming Phase III clinical trial of ecopipam in Tourette’s syndrome with a $250m series D financing barely a year

Who: Takeda/Evozyne What: Takeda is building on an earlier collaboration with the Paragon portfolio company Evozyne to discover novel protein sequences that could lead to gene therapies for rare di

Biopharmaceutical companies raised $1.5bn in 11 venture capital mega-rounds of $100m or more during the last week and a half of March. Including VC and other financings under $100m, 35 privately held